Lorenzo-Pouso AI,
Pérez-Sayáns M, González-Palanca S, Chamorro-Petronacci C, Bagán J,
García-García A. Biomarkers to predict the onset of biphosphonate-related
osteonecrosis of the jaw: A systematic review. Med Oral
Patol Oral Cir Bucal. 2019 Jan
1;24 (1):e26-36.
doi:10.4317/medoral.22763
http://dx.doi.org/doi:10.4317/medoral.22763
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
1. Kavanagh KL,
Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, et al. The molecular mechanism
of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl
Acad Sci U S A. 2006;103:7829-34. |
|
|
|
|
|
2. Fleisch H,
Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its
implications in calcium homeostasis. Nature. 1966;212:901-3. |
|
|
|
|
|
3. Russell RG.
Bisphosphonates: the first 40 years. Bone. 2011;49:2-19. |
|
|
|
|
|
4. Drake MT,
Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in
clinical practice. Mayo Clin Proc. 2008;83:1032-45. |
|
|
|
|
|
5. Stresing V,
Fournier PG, Bellahcene A, Benzaid I, Monkkonen H, Colombel M, et al.
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without
the involvement of farnesyl pyrophosphate synthase. Bone. 2011;48:259-66. |
|
|
|
|
|
6. Melton LJ
3rd, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone
turnover to bone density and fractures. J Bone Miner Res. 1997;12:1083-91. |
|
|
|
|
|
7. Khosla S,
Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al.
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of
the American Society for Bone and Mineral Research. J Bone Miner Res.
2007;22:1479-91. |
|
|
|
|
|
8. Ruggiero SL,
Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American
Association of Oral and Maxillofacial Surgeons position paper on
medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac
Surg. 2014;72:1938-56. |
|
|
|
|
|
9. Reid IR,
Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev
Rheumatol. 2011;8:90-6. |
|
|
|
|
|
10. Bagan J,
Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated
with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol.
2009;45:551-4. |
|
|
|
|
|
11. McClung MR,
Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab
in postmenopausal women with low bone mineral density. N Engl J Med.
2006;354:821-31. |
|
|
|
|
|
12. Barngkgei I,
Khattab R. Detecting the effect of bisphosphonates during osteoporosis
treatment on jawbones using multidetector computed tomography: The OSTEOSYR
project. J Investig Clin Dent. 2018;9:e12332. |
|
|
|
|
|
13. Mozzati M,
Martinasso G, Maggiora M, Scoletta M, Zambelli M, Carossa S, et al. Oral
mucosa produces cytokines and factors influencing osteoclast activity and
endothelial cell proliferation, in patients with osteonecrosis of jaw after
treatment with zoledronic acid. Clin Oral Investig. 2013;17:1259-66. |
|
|
|
|
|
14. Mawardi H,
Giro G, Kajiya M, Ohta K, Almazrooa S, Alshwaimi E, et al. A role of oral
bacteria in bisphosphonate-induced osteonecrosis of the jaw. J Dent Res.
2011;90:1339-45. |
|
|
|
|
|
15. Chen YJ,
Chao KS, Yang YC, Hsu ML, Lin CP, Chen YY. Zoledronic acid, an
aminobisphosphonate, modulates differentiation and maturation of human
dendritic cells. Immunopharmacol Immunotoxicol. 2009;31:499-508. |
|
|
|
|
|
16. Fung PL,
Nicoletti P, Shen Y, Porter S, Fedele S. Pharmacogenetics of
Bisphosphonate-associated Osteonecrosis of the Jaw. Oral Maxillofac Surg Clin
North Am. 2015;27:537-46. |
|
|
|
|
|
17. Hamadeh IS,
Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev.
2015;41:455-64. |
|
|
|
|
|
18. Marx RE.
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of
the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7. |
|
|
|
|
|
19. Marx RE,
Cillo JE,Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk
factors, prediction of risk using serum CTX testing, prevention, and
treatment. J Oral Maxillofac Surg. 2007;65:2397-2410. |
|
|
|
|
|
20. Enciso R,
Keaton J, Saleh N, Ahmadieh A, Clark GT, Sedghizadeh PP. Assessing the
utility of serum C-telopeptide cross-link of type 1 collagen as a predictor
of bisphosphonate-related osteonecrosis of the jaw: A systematic review and
meta-analysis. J Am Dent Assoc. 2016;147:551-560.e11. |
|
|
|
|
|
21. Khan AA,
Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al. Case-Based
Review of Osteonecrosis of the Jaw (ONJ) and Application of the International
Recommendations for Management From the International Task Force on ONJ. J
Clin Densitom. 2017;20:8-24. |
|
|
|
|
|
22. Liberati A,
Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA
statement for reporting systematic reviews and meta-analyses of studies that
evaluate health care interventions: explanation and elaboration. J Clin
Epidemiol. 2009;62:e1-34. |
|
|
|
|
|
23. Deeks JJ,
Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating
non-randomised intervention studies. Health Technol Assess. 2003; 7:iii-x,
1-173. |
|
|
|
|
|
24. Burns PB,
Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based
medicine. Plast Reconstr Surg 2011;128:305-10. |
|
|
|
|
|
25. Kunchur R,
Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking
telopeptide test in prevention and management of bisphosphonate-associated
osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67:1167-73. |
|
|
|
|
|
26. Lazarovici
TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al.
Serologic bone markers for predicting development of osteonecrosis of the jaw
in patients receiving bisphosphonates. J Oral Maxillofac Surg.
2010;68:2241-7. |
|
|
|
|
|
27. Vincenzi B,
Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, et al. Serum
VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of
the jaw. J Hematol Oncol. 2012;5:56-8722-5-56. |
|
|
|
|
|
28. Kim JW, Kong
KA, Kim SJ, Choi SK, Cha IH, Kim MR. Prospective biomarker evaluation in
patients with osteonecrosis of the jaw who received bisphosphonates. Bone.
2013;57:201-5. |
|
|
|
|
|
29. Migliorati
CA, Saunders D, Conlon MS, Ingstad HK, Vaagen P, Palazzolo MJ, et al.
Assessing the association between bisphosphonate exposure and delayed mucosal
healing after tooth extraction. J Am Dent Assoc. 2013;144:406-14. |
|
|
|
|
|
30. Hutcheson A,
Cheng A, Kunchar R, Stein B, Sambrook P, Goss A. A C-terminal crosslinking
telopeptide test-based protocol for patients on oral bisphosphonates
requiring extraction: a prospective single-center controlled study. J Oral
Maxillofac Surg. 2014; 72:1456-62. |
|
|
|
|
|
31. Topaloglu G,
Koseoglu OT, Karaca C, Kosemehmetoglu K. The effect of chronic dental
inflammation on development of Stage 0 medication-related osteonecrosis of
the jaw. J Craniomaxillofac Surg. 2017;45:1158-64. |
|
|
|
|
|
32. Bagan JV,
Jimenez Y, Gomez D, Sirera R, Poveda R, Scully C. Collagen telopeptide (serum
CTX) and its relationship with the size and number of lesions in
osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.
Oral Oncol. 2008;44:1088-9. |
|
|
|
|
|
33. Lee JJ,
Cheng SJ, Wang JJ, Chiang CP, Chang HH, Chen HM, et al. Factors predicting
the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year
cohort study. Head Neck. 2013; 35:1787-95. |
|
|
|
|
|
34. Bagan L,
Jimenez Y, Leopoldo M, Rubert A, Bagan J. Serum levels of RANKL and OPG, and
the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are
they useful biomarkers for the advanced stages of osteonecrosis?. Med Oral
Patol Oral Cir Bucal. 2017;22:e542-e7. |
|
|
|
|
|
35.
Thumbigere-Math V, Michalowicz BS, Hughes PJ, Basi DL, Tsai ML, Swenson KK,
et al. Serum Markers of Bone Turnover and Angiogenesis in Patients With
Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of
Long-Term Intravenous Bisphosphonate Therapy. J Oral Maxillofac Surg.
2016;74:738-46. |
|
|
|
|
|
36. Bundred N.
Antiresorptive therapies in oncology and their effects on cancer progression.
Cancer Treat Rev. 2012; 38:776-86. |
|
|
|
|
|
37. McGowan K,
McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of
the jaws: A systematic review. Oral Dis. 2018;24:527-36. |
|
|
|
|
|
38. Calvo MS,
Eyre DR, Gundberg CM. Molecular basis and clinical application of biological
markers of bone turnover. Endocr Rev. 1996;17:333-68. |
|
|
|
|
|
39. Baim S,
Miller PD. Assessing the clinical utility of serum CTX in postmenopausal
osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J
Bone Miner Res. 2009;24:561-74. |
|
|
|
|
|
40. Dal Pra KJ,
Lemos CA, Okamoto R, Soubhia AM, Pellizzer EP. Efficacy of the C-terminal
telopeptide test in predicting the development of bisphosphonate-related
osteonecrosis of the jaw: a systematic review. Int J Oral Maxillofac Surg.
2017;46:151-6. |
|
|
|
|
|
41. Migliorati
CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a
long-term complication of bisphosphonate treatment. Lancet Oncol.
2006;7:508-14. |
|
|
|
|
|
42. Cackowski
FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, et al.
Osteoclasts are important for bone angiogenesis. Blood. 2010;115:140-9. |
|
|
|
|
|
43. Beninati F,
Pruneti R, Ficarra G. Bisphosphonate-related osteonecrosis of the jaws
(Bronj). Med Oral Patol Oral Cir Bucal. 2013;18:e752-8. |
|
|
|
|
|
44.
Thumbigere-Math V, Michalowicz BS, de Jong EP, Griffin TJ, Basi DL, Hughes
PJ, et al. Salivary proteomics in bisphosphonate-related osteonecrosis of the
jaw. Oral Dis. 2015;21:46-56. |
|
|
|
|
|
45. De Colli M,
Tortorella P, Marconi GD, Agamennone M, Campestre C, Tauro M, et al. In vitro
comparison of new bisphosphonic acids and zoledronate effects on human
gingival fibroblasts viability, inflammation and matrix turnover. Clin Oral
Investig. 2016;20:2013-21. |
|
|
|
|
|
46. Ardine M,
Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could the
long-term persistence of low serum calcium levels and high serum parathyroid
hormone levels during bisphosphonate treatment predispose metastatic breast
cancer patients to undergo osteonecrosis of the jaw?. Ann Oncol.
2006;17:1336-7. |
|
|
|
|
|
47. Bagan J,
Saez GT, Tormos MC, Gavalda-Esteve C, Bagan L, Leopoldo-Rodado M, et al.
Oxidative stress in bisphosphonate-related osteonecrosis of the jaws. J Oral
Pathol Med. 2014;43:371-7. |
|
|
|
|
|
48. Bagan J,
Saez GT, Tormos MC, Hens E, Terol MJ, Bagan L, et al. Interleukin-6
concentration changes in plasma and saliva in bisphosphonate-related
osteonecrosis of the jaws. Oral Dis. 2014;20:446-52. |
|
|
|
|
|
49. Bagan J,
Sheth CC, Soria JM, Margaix M, Bagan L. Bisphosphonates-related osteonecrosis
of the jaws: a preliminary study of salivary interleukins. J Oral Pathol Med.
2013;42:405-8. |
|